BACE1 and Alzheimer disease: We demonstrated that the BACE1 inhibitor MK-8931, which has been tested in clinical trials for AD treatment, could effectively converts proinflammatory microglia into an anti-inflammatory state and promotes phagocytosis of hematoma in vitro and in vivo.